Nakstad excludes vaccines for children between 12 and 15 years before the autumn

The study found that none of the 2,260 vaccinated children were infected with coronary heart disease. The Pfizer vaccine is currently approved for people aged 16 and up.

– This is a vaccine that has already been used many millions of times, and which has temporary approval for use over 16 years, says assistant health director Espen Nakstad to Dagbladet.

– Then it remains to document that there are no problems with side effects and that it also shows a good effect in those under 16, he says.

– Things change fast

But the way the approval process is set up means that it will not be relevant until after the summer, Nakstad believes.

– It looks like the race that has been put in place for approval, means that this will not be relevant until after the summer. We do not know for sure, but at least it looks like most adults will be offered vaccines towards the summer. In terms of time, it may be that this offer appears after the adults have been vaccinated, says Nakstad.

– But here things change quite quickly in terms of vaccine deliveries as well, he says.

In Europe, Pfizer-Biontech must apply for approval from the European Medicines Agency (EMA) before the Norwegian Medicines Agency agrees to such use.

May take a few months

The process can take one to two months, according to Geir Bukholm, who heads the vaccine program at the National Institute of Public Health (NIPH).

– Then children up to the age of twelve will be a group that we will eventually consider including in the vaccination program, Bukholm told NTB on Wednesday.

The coronary vaccines of Pfizer, Moderna, AstraZeneca and Johnson & Johnson are approved for use in Norway. The AstraZeneca vaccine has been paused following reports of possible serious side effects.